Know Cancer

forgot password

Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study

18 Years
Open (Enrolling)
Sickle Cell Disease

Thank you

Trial Information

Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study

Inclusion Criteria:

1. Patients with sickle cell disease .

2. Patients who are 18 years of age or older.

3. Patients presenting for follow up at the outpatient sickle cell clinic.

4. Patients who are capable of following simple instructions.

5. Patients who are able and willing to provide informed consent.

Exclusion Criteria:

1. History of lung infection, asthma, acute chest syndrome, or Chronic Obstructive
Pulmonary Disease (COPD) exacerbation in the past 2 weeks.

2. Significant pulmonary dysfunction, defined clinically as respiratory illness
secondary to any etiology, in the past 3-6 months.

3. Active vaso-occlusive crisis, or exacerbated pain within the last 2 weeks.

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Exhaled Carbon Monoxide Level

Outcome Description:

Exhaled Carbon Monoxide Levels will be measured at regular scheduled follow up visits.

Outcome Time Frame:

participants will be followed for the duration of two years, during their scheduled clinic visits (expected average of 24 visits)

Safety Issue:


Principal Investigator

Jane Little, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospital Case Medical Center


United States: Institutional Review Board

Study ID:




Start Date:

June 2013

Completion Date:

June 2015

Related Keywords:

  • Sickle Cell Disease
  • carbon mono oxide
  • sickle cell
  • hemolysis
  • Anemia, Sickle Cell
  • Hemolysis



Seidman Cancer Center, University HospitalsCleveland, Ohio  44106